Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360165 | 0.95 | TRPV1 (0.72) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1982942 | 0.93 | TRPV1 (0.77) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1983121 | 0.92 | TRPV1 (0.75) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2359409 | 0.89 | TRPV1 (1.00) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL1981340 | 0.89 | TRPV1 (1.00) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2358859 | 0.85 | TRPV1 (0.78) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL3321386 | 0.84 | TRPV1 (0.77) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL4348324 | 0.84 | TRPV1 (0.75) | TRPV1CYP3A4 | |
| SCHEMBL2357332 | 0.83 | TRPV1 (0.90) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2315125 | 0.83 | TRPV1 (0.90) | TRPV1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | claimed |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | claimed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | claimed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | claimed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | claimed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8440691-B2 | Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | TRPV1 24/4885CYP3A4 953/4885CYP2D6 1146/4885 |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1282/4885CYP2D6 878/4885 |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | CACNA1E, CACNA1D, CACNA1S | TRPV1 24/4885CYP3A4 953/4885CYP2D6 1146/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CYP3A4 1264/4885CYP2D6 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.